Insmed’s gene therapy poised to challenge DMD landscape after IND clearance
Currently, the DMD treatment landscape includes Sarepta’s Elevidys (delandistrogene moxeparvovec), the first FDA-approved ...
FDA Grants Orphan Drug Designation to IPS HEART’s GIVI-MPC Stem Cell Therapy for Becker Muscular Dystrophy
IPS HEART has been awarded Orphan Drug Designation (ODD) by the FDA for GIVI-MPCs based on its unique ability to create new ...
Hosted on MSN25d
Lifechanging new drug successfully treats Duchenne muscular dystrophy
Characterized by progressive muscle degeneration, this X-linked disorder results from mutations in the DMD gene, which encodes dystrophin, a protein essential for maintaining muscle cell integrity.
Science Daily16d
New study uncovers key insights into protein interactions in Duchenne muscular dystrophy, paving way for more targeted therapies
A groundbreaking study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein, dystrobrevin, offering new pathways for ...
Medindia15d
Advancing Duchenne Muscular Dystrophy Treatments Through Protein Interactions
New study reveals crucial protein interactions in Duchenne Muscular Dystrophy, opening doors to more precise and effective ...
Muscular Dystrophy News8d
Application finalized for DMD cell therapy CAP-1002, now deramiocel
Capricor's biologics license application for deramiocel (CAP-1002) is draws largely on the Phase 2 HOPE-2 trial and its ...
Daily12d
Study Highlights Critical Protein Interactions In Duchenne Muscular Dystrophy
A new study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its ...
Managed Healthcare Executive12d
Capricor Completes BLA for Deramiocel for Duchenne Cardiomyopathy
Deramiocel is a cell therapy that has healing effects in muscle cells. If approved, deramiocel would be a once-quarterly ...
BioWorld2d
Ips Heart’s stem cell therapy designated orphan drug for Becker muscular dystrophy
Ips Heart Inc. has been awarded orphan drug designation by the FDA for its GIVI-MPC stem cell therapy for Becker muscular dystrophy. GIVI-MPC has the unique ability to create new muscle with full ...